Previous Page
What is INQOVI?
Next Page
Efficacy & Safety
Treatment-naive
Patient Profile:
Gregory, 71
Diagnosis
- Diagnosed with high-risk MDS when a blood examination revealed pancytopenia
- Bone marrow biopsy indicated 10% blasts and multilineage dysplasia
Blood Test Results
- Hemoglobin: 6.0 g/dL
- Red blood cells: 4.1 M/µL
- White blood cells: 3.0 K/µL
- ANC: 570 cells/µL*
- IPSS-R Score of 5.5 points=high
- Platelets: 76 x 109/L
- Neutrophils: 16%
- Cytogenetic category: Good
About Gregory
- He enjoys fishing and doing outdoor activities with his wife and 2 grandchildren
- He is transfusion-dependent
- His treatment team discussed hypomethylating agents due to his IPSS-R Score, but Gregory does not have to have a port placement
- He would prefer a treatment option that he can take in the convenience of his home
- ECOG performance status was 1 prior to taking INQOVI
*Bands: 3%
ANC=absolute neutrophil count; ECOG=Eastern Cooperative Oncology Group; IPSS-R=Revised International Prognostic Scoring System; MDS=myelodysplastic syndromes.
Treatment-switch
Patient Profile:
Diane, 74
Diagnosis
- Diagnosed 6 months ago with intermediate-risk MDS
- Tests revealed moderate anemia, neutropenia; there was a prior diagnosis of renal disease
- 11.2% blasts
- Initiated MDS treatment with IV HMA therapy
- Began transfusion for anemia, and monitored progress
- Has since achieved transfusion independence and is stable
Blood Test Results
- Hemoglobin: 6.5 g/dL
- Red blood cells: 3.6 M/µL
- White blood cells: 4.0 K/µL
- ANC: 800 cells/µL†
- IPSS-R Score of 4.5 points=intermediate
- Platelets: 103 x 109/L
- Neutrophils: 18%
- Cytogenetic category: Very good
About Diane
- She does not have a full-time caregiver or family member to help with travel; she has been unable to get to the infusion center to complete her most recent cycle
- She needed a treatment option she could take at home
- ECOG performance status of 2 prior to beginning INQOVI
†Bands: 2%
Additional Information
Your patients who may be appropriate for INQOVI1
- Diagnosed with de novo or secondary MDS, including CMML
- Classified as intermediate- or high-risk MDS
- Are treatment naive
- Have previously been treated, and may be ready to switch from current treatment
Additional Patient Considerations1,2:
- Wish to take their HMA therapy in the comfort of their own home
- Unable to have, or do not wish to have, infusion port placement
- Cannot manage travel to the infusion center
CMML=chronic myelomonocytic leukemia.
*Click here for full dosing information.